Predictive factors of efficacy of combination therapy with basal insulin and liraglutide in type 2 diabetes when switched from longstanding basal-bolus insulin: Association between the responses of β- and α-cells to GLP-1 stimulation and the glycaemic control at 6 months after switching therapy

Horie, Ichiro; Haraguchi, Ai; Sako, Ayaka; Akeshima, Junya; Niri, Tetsuro; Shigeno, Riyoko; Ito, Ayako; Nozaki, Aya; Natsuda, Shoko; Akazawa, Satoru; Mori, Yoshitaka; Ando, Takao; Kawakami, Atsushi; Abiru, Norio

doi:10.1016/j.diabres.2018.08.015

Cited by 6 publications

(7 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We further investigated clinical characteristics of patients who have shown good response to SGLT2 inhibitor therapy. We defined good responders as those with HbA1c <7.0% or a decrease in HbA1c of more than 1.0% at 12 weeks after SGLT2 inhibitor therapy [20].…”

Section: Methodsmentioning

confidence: 99%

Efficacy and Safety of Sodium-Glucose Cotransporter-2 Inhibitors in Korean Patients with Type 2 Diabetes Mellitus in Real-World Clinical Practice

et al. 2019

View full text Add to dashboard Cite

BackgroundThis study aimed to evaluate the efficacy and safety of sodium-glucose cotransporter-2 (SGLT2) inhibitors in Korean patients who had inadequately controlled type 2 diabetes mellitus (T2DM) in real-world clinical practice.MethodsWe included 410 patients who started SGLT2 inhibitors (empagliflozin or dapagliflozin) as add-on therapy or switch therapy between February 2015 and June 2017. The primary efficacy endpoint was a change in glycosylated hemoglobin (HbA1c) from baseline to week 12. The secondary endpoints were patients achieving HbA1c <7.0% and changes in the fasting plasma glucose (FPG), lipid profiles, body weight, and blood pressure (BP).ResultsThe mean HbA1c at baseline was 8.5% (8.6% in the add-on group and 8.4% in the switch group). At week 12, the mean adjusted HbA1c decreased by −0.68% in the overall patients (P<0.001), by −0.94% in the add-on group, and by −0.42% in the switch group. Significant reductions in FPG were also observed both in the add-on group and switch group (−30.3 and −19.8 mg/dL, respectively). Serum triglyceride (−16.5 mg/dL), body weight (−2.1 kg), systolic BP (−4.7 mm Hg), and diastolic BP (−1.3 mm Hg) were significantly improved in the overall patients. Approximately 18.3% of the patients achieved HbA1c <7.0% at week 12. A low incidence of hypoglycemia and genital tract infection was observed (6.3% and 2.2%, respectively).ConclusionSGLT2 inhibitors can be a suitable option as either add-on or switch therapy for Korean patients with inadequately controlled T2DM.

show abstract

Section: Methodsmentioning

confidence: 99%

Efficacy and Safety of Sodium-Glucose Cotransporter-2 Inhibitors in Korean Patients with Type 2 Diabetes Mellitus in Real-World Clinical Practice

et al. 2019

View full text Add to dashboard Cite

show abstract

“…The search terms are presented in Table S1. The search results were discussed by the author group and relevant articles were identified; 19–33 these are summarised in Tables 1 and 2 19–33 …”

Section: Methodsmentioning

confidence: 99%

“…The search terms are presented in Table S1. The search results were discussed by the author group and relevant articles were identified; [19][20][21][22][23][24][25][26][27][28][29][30][31][32][33] these are summarised in Tables 1 and 2. [19][20][21][22][23][24][25][26][27][28][29][30][31][32][33]…”

Section: Methodsmentioning

confidence: 99%

“…In a study by Horie and colleagues, glycaemic control was assessed in 41 people with type 2 diabetes transitioning from long-term (>3 years) BBI therapy to basal insulin and liraglutide. 26 Six months after changing treatment, 68.3% of participants had achieved a HbA1c level <53 mmol/mol (<7.0%), or a >11 mmol/mol (>1.0%) decrease in HbA1c. 26 Yamamoto and colleagues conducted a 24-week, randomised, parallel-group, open-label trial investigating the superiority of basal insulin and liraglutide (n = 12) compared with continued BBI therapy (n = 13) in Japanese people with type 2 diabetes.…”

Section: Transitioning From Basal-bolus Insulin Therapy To a Loose Co...mentioning

confidence: 95%

“…In a study by Horie and colleagues, glycaemic control was assessed in 41 people with type 2 diabetes transitioning from long‐term (>3 years) BBI therapy to basal insulin and liraglutide 26 . Six months after changing treatment, 68.3% of participants had achieved a HbA1c level <53 mmol/mol (<7.0%), or a >11 mmol/mol (>1.0%) decrease in HbA1c 26 …”

Section: Overview Of the Clinical Evidence For Transitioning To A Com...mentioning

confidence: 99%

See 2 more Smart Citations

Transitioning from basal–bolus or premix insulin therapy to a combination of basal insulin and glucagon‐like peptide‐1 receptor agonist in people with type 2 diabetes

et al. 2022

View full text Add to dashboard Cite

Aims: Two fixed-ratio combinations (FRCs) of basal insulin and glucagon-like peptide-1 receptor agonist (GLP-1RA) are available for once-daily use in adults with type 2 diabetes. We aimed to review the clinical evidence for the efficacy and safety of changing treatment from a basal-bolus insulin (BBI) regimen or a premix insulin to these combination treatments (fixed-ratio or loose) and provide expert opinion on the practicalities of making such a change. Methods: Relevant clinical and trial evidence and general review articles were identified through a literature review of ProQuest (comprising BIOSIS Previews®, Current Contents® Search, Embase® and MEDLINE®) for articles published between 2009 and 2021. Results:We identified nine articles reporting the results of FRCs, and seven articles reporting results of loose combinations of basal insulin and GLP-1RAs, in people who transitioned treatment from BBI or premix regimens. In most trials, combination treatment led to improved or equivalent glycaemic control, and a reduction in body weight or BMI, versus the original regimens. Some trials reported a reduction in total insulin dose. A few trials reported reduced or unchanged hypoglycaemia rates, or increased patient satisfaction, with combination therapy where these endpoints were examined. We provide guidance on transitioning of treatment and the patient types most likely to benefit. Conclusions:In people not achieving glycaemic control with BBI or premix insulin regimens, an FRC or loose combination of basal insulin and GLP-1RA may improve control, decrease the risk of body weight gain or hypoglycaemia and reduce the complexity of treatment.

show abstract

Type II diabetes mellitus: a review on recent drug based therapeutics

Padhi

Nayak

Behera

2020

Biomedicine & Pharmacotherapy

411

144

View full text Add to dashboard Cite

Predictive factors of efficacy of combination therapy with basal insulin and liraglutide in type 2 diabetes when switched from longstanding basal-bolus insulin: Association between the responses of β- and α-cells to GLP-1 stimulation and the glycaemic control at 6 months after switching therapy

Abstract: Enhancement of glucose-dependent insulin-response under liraglutide administration is a potential predictor of long-term glycaemic control after switching the therapies.

Cited by 6 publications

References 30 publications

Efficacy and Safety of Sodium-Glucose Cotransporter-2 Inhibitors in Korean Patients with Type 2 Diabetes Mellitus in Real-World Clinical Practice

Efficacy and Safety of Sodium-Glucose Cotransporter-2 Inhibitors in Korean Patients with Type 2 Diabetes Mellitus in Real-World Clinical Practice

Transitioning from basal–bolus or premix insulin therapy to a combination of basal insulin and glucagon‐like peptide‐1 receptor agonist in people with type 2 diabetes

Type II diabetes mellitus: a review on recent drug based therapeutics

Contact Info

Product

Resources

About

Predictive factors of efficacy of combination therapy with basal insulin and liraglutide in type 2 diabetes when switched from longstanding basal-bolus insulin: Association between the responses of β- and α-cells to GLP-1 stimulation and the glycaemic control at 6 months after switching therapy

Abstract: Enhancement of glucose-dependent insulin-response under liraglutide administration is a potential predictor of long-term glycaemic control after switching the therapies.

Cited by 6 publications

References 30 publications

Efficacy and Safety of Sodium-Glucose Cotransporter-2 Inhibitors in Korean Patients with Type 2 Diabetes Mellitus in Real-World Clinical Practice

Efficacy and Safety of Sodium-Glucose Cotransporter-2 Inhibitors in Korean Patients with Type 2 Diabetes Mellitus in Real-World Clinical Practice

Transitioning from basal–bolus or premix insulin therapy to a combination of basal insulin and glucagon‐like peptide‐1 receptor agonist in people with type 2 diabetes

Type II diabetes mellitus: a review on recent drug based therapeutics

Contact Info

Product

Resources

About

Predictive factors of efficacy of combination therapy with basal insulin and liraglutide in type 2 diabetes when switched from longstanding basal-bolus insulin: Association between the responses of β- and α-cells to GLP-1 stimulation and the glycaemic control at 6 months after switching therapy